From Bench to Bedside: Advances in Non-small Cell Lung Cancer in the Era of Precision Oncology

Dear Colleagues,

Non-small-cell lung cancer (NSCLC) is a leading cause of cancer-related mortality worldwide. Recent progress in the understanding of molecular mechanisms of NSCLC initiation and progression has led to the identification of novel biomarkers for diagnosis and therapy. A better understanding of the interplay between intrinsic cancer cell mechanisms and the extrinsic tumor microenvironment is a gateway towards innovation and biomarker development in immune checkpoint inhibition (ICI) therapy. Advances in next-generation sequencing have made comprehensive genomic profiling (CGP) a mainstay for therapy selection. Techniques such as liquid biopsy in the management of NSCLC enable the noninvasive acquisition of diagnostic and surveillance samples with reduced patient morbidity and cost to the healthcare system. The use of diagnostic predictive modeling has further advanced the goals of precision medicine.

This Special Issue on NSCLC aims to highlight recent advances from bench-to-bedside research in NSCLC in the era of genomics and precision medicine. We seek original basic and translational studies and review articles in NSCLC pathogenesis, biomarker discovery, and development and laboratory genomic medicine. The scope of this Special Issue includes the following:

1. Advances in the molecular pathogenesis of NSCLC.
2. Advances in molecular methods for NSCLC diagnosis, including CGP.
3. Identification of novel biomarkers and predictive machine learning modeling of molecular biomarkers, targeted therapy, and ICI therapy for risk stratification and patient outcomes.
4. Advances in liquid biopsy in NSCLC.

Dr. Iyare Izevbaye
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• non-small-cell lung cancer
• precision medicine
• liquid biopsy
• biomarkers
• predictive modeling
• comprehensive genomic profiling
• biomarkers
• immuno-oncology
• lung cancer biology